This review discusses the multiple bio‐ and nanotechnological strategies developed in the last few decades for treatment of a group of fatal genetic diseases termed lysosomal storage disorders. Some basic foundation on the biomedical causes and social and clinical relevance of these diseases is provided. Several treatment modalities, from those currently available to novel therapeutic approaches under development, are also discussed; these include gene and cell therapies, substrate reduction therapy, chemical chaperones, enzyme replacement therapy, multifunctional chimeras, targeting strategies, and drug carrier approaches. WIREs Nanomed Nanobiotechnol 2010 2 189–204 This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies
No takes yet. Share an insight, caveat, or question.
Silvia Muro (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: